GlaxoSmithKline PLC Directorate Change
RNS Number : 2672K
04 May 2022
Issued: 4 May 2022, London UK - LSE announcement
GSK announces Dr Vishal Sikka to join the Board as Non-Executive
GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr
Vishal Sikka, founder and CEO of Vianai Systems, will join the
Board of the Company as a Non-Executive Director. He will join the
Board with effect from the Haleon demerger.
Vishal has a distinguished background in technology and
particularly in the field of Artificial Intelligence (AI) and
Machine Learning, which is central to GSK's approach to R&D. He
is the founder and CEO of Vianai Systems, a Silicon Valley-based
company that provides advanced technological software and services
in AI and Machine Learning to large enterprises around the world.
Prior to founding Vianai Systems, Vishal served as CEO of Infosys
and as a member of the Executive Board of SAP SE. Vishal has a PhD
in Artificial Intelligence from Stanford University and has
co-authored several research abstracts related to AI, technology
and database management. He is also currently a Board member of
Oracle Corporation and BMW.
Commenting on the appointment, Sir Jonathan Symonds, Chair of
GSK said: "I am delighted to welcome Vishal to GSK. He is an
experienced board director and an outstanding technologist who has
been at the forefront of advanced technologies such as AI and
Machine Learning for decades. Harnessing and applying these
technologies to the discovery and development of new medicines and
vaccines is central to our R&D approach, and Vishal's insight
and expertise will be invaluable as the company accelerates its
efforts in this area."
Vishal's appointment further strengthens the Board's expertise
and builds on other recent Non-Executive Director appointments,
including Dr Harry (Hal) C. Dietz, Professor of Genetic Medicine at
The Johns Hopkins University School of Medicine; Charles (Charlie)
Bancroft, former Executive Vice President at Bristol Myers Squibb
(BMS), and Dr Anne Beal, former instructor in paediatrics at
Harvard Medical School and Massachusetts General Hospital, and
Chief Patient Officer at Sanofi.
A further non-executive appointment, with deep biopharma
expertise, is expected in July 2022.
1. The appointment of Dr Vishal Sikka was made by the Board
on the recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external
search firm, which is a signatory of the Voluntary Code
of Conduct for Executive Search Firms. The external search
firm provided a diverse list of candidates who were approached,
evaluated and interviewed, against an agreed set of criteria
aligned to the Board's target skills matrix.
2. The Board has determined that Dr Sikka will be an independent
Non-Executive Director on appointment in accordance with
the UK Corporate Governance Code.
3. Dr Sikka will receive the standard basic fee for a Non-Executive
Director of GBP95,000 per annum.
(Dr Sikka will be required to invest in GSK shares in accordance
with the Company's shareholder approved Non Executive remuneration
4. Membership of other Committees will be announced in due
5. Dr Sikka does not have a service contract. He has a letter
of appointment which may be viewed by contacting the Company
Secretary at the Company's registered office.
6. There are no further disclosures to be made in respect of
Dr Sikka's appointment under Listing Rule 9.6.13R.
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us .
Media enquiries: Tim Foley +44 (0) 20 8047 (London)
Kathleen Quinn +1 202 603 5003 (Washington
Analyst/Investor Nick Stone +44 (0) 7717 618834 (London)
Sonya Ghobrial +44 (0) 7392 784784 (Consumer)
James Dodwell +44 (0) 20 8047 (London)
Mick Readey +44 (0) 7990 339653 (London)
Josh Williams +44 (0) 7385 415719 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
980 Great West Road
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
May 04, 2022 05:00 ET (09:00 GMT)
Historical Stock Chart
From Jun 2022 to Jul 2022
Historical Stock Chart
From Jul 2021 to Jul 2022